Advertisement

NEXT ARTICLE

Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer

08:30 EST 4 Jan 2012 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecul...

Other Sources for this Article

Businesswire

 Channels 44 Associated Channels :: Search

Associated Content for this Article